Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EMQPK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SYD1875
|
|||||
| Synonyms |
SYD1875
Click to Show/Hide
|
|||||
| Organization |
Byondis (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
SYD1594
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Seco-DUBA
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
duocarmazine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: Histologically-confirmed advanced/metastatic cancer (Part 1: any solid tumor; Part 2: 3 predefined cohorts) with 5T4 membrane staining, ECOG ≤1, adequate organ function (Part 2 requires measurable disease). Exclusion: Prior 5T4/SYD985 therapy, recent anticancer/hormone therapy (4w/1w), active keratitis/significant organ dysfunction, symptomatic brain metastases or treatment within 8w.
Click to Show/Hide
|
||||
| Administration Dosage |
SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04202705 | Clinical Status | PHASE1 | ||
| Clinical Description | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours | ||||
| Primary Endpoint |
Incidence of dose-limiting toxicities
|
||||
| Other Endpoint |
Objective response rate
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04202705 | Clinical Status | Phase 1 | ||
| Clinical Description | A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours. | ||||
References